Advancements in Multiple Myeloma Treatment: Frontline Approaches and Therapies for Early Relapse : Episode 4
Insights of MAIA, BENEFIT, and IMROZ Trials on Frontline Treatment for Transplant Not-Preferred NDMM
Panelists discuss how recent clinical trials have demonstrated improved outcomes with antibody-containing regimens and biomarker-driven approaches in patients with transplant not-preferred newly diagnosed multiple myeloma (NDMM).
EP: 1.Current Strategies for Frontline Therapy in Transplant-Preferred NDMM
EP: 2.Brief Overview of PERSEUS, IsKia, and CASSIOPEIA Clinical Trials
EP: 3.Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations
Now Viewing
EP: 4.Insights of MAIA, BENEFIT, and IMROZ Trials on Frontline Treatment for Transplant Not-Preferred NDMM
EP: 5.Initial Impressions of the CEPHEUS Clinical Trial in Transplant Not-Preferred NDMM
EP: 6.Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial
Video content above is prompted by the following:
- What are your perspectives on the data from the MAIA, BENEFIT, and IMROZ trials?
- How does the data impact frontline treatment for patients with NDMM who are not transplant-preferred?
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
